Trinity Biotech (TRIB) Non-Current Debt (2009 - 2025)

Trinity Biotech (TRIB) has reported Non-Current Debt for 15 consecutive years, with $210000.0 the latest figure, recorded in Q2 2025.

• Quarterly Non-Current Debt changed 0.0% year-over-year to $210000.0 in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $210000.0 (changed 0.0% YoY) and the FY2024 annual result came in at $210000.0, changed 0.0% from the prior year.
• Non-Current Debt steadied at $210000.0 in Q2 2025 per TRIB's latest filing, from $210000.0 in the prior quarter.
• Over the last five years, Non-Current Debt for TRIB reached as high as $84.0 million in Q1 2021 and fell as low as $210000.0 in Q3 2022.
• A 5-year average of $26.8 million and a median of $210000.0 in 2022 frame the typical range for Non-Current Debt.
• Annual changes were most pronounced in 2021 — Non-Current Debt climbed 2.26% — and 2022, when it tumbled 99.75%.
• Year by year, Non-Current Debt stood at $83.3 million in 2021, then slumped by 99.75% to $210000.0 in 2022, then changed by 0.0% to $210000.0 in 2023, then changed by 0.0% to $210000.0 in 2024, then changed by 0.0% to $210000.0 in 2025.
• According to Business Quant data, Non-Current Debt over the past three periods registered $210000.0, $210000.0, and $210000.0 for Q2 2025, Q4 2024, and Q3 2024 respectively.